Mizuho Securities Reiterates Buy on ATARA Biotherapeutics (ATRA) Following 4Q

Mizuho Securities analyst, Salim Syed, reiterated a Buy rating and $62.00 price target on Atara Biotherapeutics (NASDAQ: ATRA) following the company's 4Q earnings report and $100mm equity shelf.

The Street seems to be interpreting the release/shelf as a negative. Syed views the update as simply a "clarifying language on milestones timing for 2019". On a fundamental basis, the story is still the same.

For an analyst ratings summary and ratings history on Atara Biotherapeutics click here. For more ratings news on Atara Biotherapeutics click here.

Shares of Atara Biotherapeutics closed at $37.26 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Cisco rating cut at HSBC as analyst sees a lack of catalysts